welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Upcoming events – pivotal data loom for Novavax and Mallinckrodt
Welcome to your weekly digest of approaching regulatory and clinical readouts. Novavax is up 4% today thanks to topline results from a phase II trial showing that its Nanoflu influenza vaccine caused “vigorous immune responses” to four strains of flu, and that these responses were enhanced when the group’s Matrix-M adjuvant was added to the vaccine.
But an even more meaningful event is approaching. Novavax’s lead asset, a vaccine against respiratory syncytial virus, is in phase III, and after its disastrous failure two years ago in a study that was intended to be pivotal this is its last chance.
Resvax, also known as RSV F Vaccine since it targets the fusion protein of the virus, crashed out of the Resolve trial, testing it in prevention of moderate to severe RSV-associated lower respiratory tract disease, in mid-2016.
expertly curated content related to this topic
-
Extracolonic Manifestations of Hereditary Colorectal Cancer SyndromesFamilial colorectal adenocarcinoma (CRC)...
-
Prevalence and Risk Factors for Adenomas in the Ileal Pouch and the Afferent Loop After Restorative Proctocolectomy ...BACKGROUND : Restorative proctocolectomy...
-
Desmoid Tumors — Dangerous when not Treated as Cancerhttps://www.youtube.com/watch?v=gPcEJ8kA...
-
Colorectal Cancer: Are Genetic Tests Clinically Useful?More than 1.2 million new cases of color...
-
Health Promotion: Familial Adenomatous Polyposishttps://www.youtube.com/watch?v=H7STJHsN...
-
Evaluating Causes of Death in Familial Adenomatous PolyposisBACKGROUND : Familial adenomatous polypo...